At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 957 enrolled
Drug / intervention
semaglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating semaglutide, liraglutide, and 1 other intervention for Metabolism and Nutrition Disorder and Obesity. Completed, enrolled 957 participants across 74 sites in 8 countries.
Detailed Summary
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolism and Nutrition Disorder, Obesity
CountriesAustralia, Belgium, Canada, Germany, Israel, Russia, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartOct 2015
Primary CompletionMar 2017
Study CompletionApr 2017
TodayJul 2026
First PostedMay 25, 2015
Enrollment StartOct 1, 2015
Primary CompletionMar 30, 2017
Study CompletionApr 12, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.1 years ago
Interventions
semaglutidedrug
Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
liraglutidedrug
Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
placebodrug
Once-daily subcutaneous (s.c., under the skin) administration.